IDB-1829 / Interdict Bio - LARVOL DELTA

Study to evaluate the safety, effects, and early effectiveness of IDB-1829 in combination with Enzalutamide in patients with advanced prostate cancer (ANZCTR) - P2 | N=6 | Not yet recruiting | Sponsor: Interdict Bio

First-in-human • New P2 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor